Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03609112 : Neurocognitive Risks in Children With Solid Tumors
Phase
AgesMin: N/A Max: N/A
Eligibility
Inclusion Criteria:

- Patient aged 6 to 16 years and 11 months during the study period (2014-2016)

- Type of pathology: solid tumor

- Place of treatment and follow-up: Gustave Roussy

- Minimum time from the end of the initial treatment:

- For patients who have not received treatment with methotrexate: 6 months

- For patients being treated with methotrexate: none

- Obtaining the non-opposition of parents / legal representatives

- Affiliation to a social security scheme.

Exclusion Criteria:

- Patients with other pathologies associated with mental retardation (autism, genetic
syndrome ...)

- Patients lost to follow-up

- Deceased patients

- Patients treated for a pathology whose prognosis is involved in the very short term
(infiltrating glioma of the brainstem, recurrence of the pathology during treatment)

- Non-French speaking patients
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03609112      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740